Quick Answer
KalVista Pharmaceuticals, Inc. reported Total Assets of $250.77 million for the year ending 2025.
- KalVista Pharmaceuticals, Inc. showed an increase of +6.5% in Total Assets from 2024 to 2025.
- This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $7.71 million | Q2 2015: $67.60 million | Q3 2015: $62.08 million | Q4 2015: $56.79 million | Q1 2016: $49.68 million | Q2 2016: $38.01 million | Q3 2016: $35.86 million | Q1 2017: $38.05 million | Q3 2017: $30.78 million | Q4 2017: $34.74 million | Q1 2018: $66.66 million | Q3 2018: $57.62 million | Q4 2018: $132.56 million | Q1 2019: $126.53 million | Q3 2019: $119.88 million | Q4 2019: $112.06 million | Q1 2020: $102.94 million | Q3 2020: $83.90 million | Q4 2020: $75.45 million | Q1 2021: $66.21 million | Q3 2021: $259.13 million | Q4 2021: $243.81 million | Q1 2022: $225.05 million | Q3 2022: $182.32 million | Q4 2022: $162.84 million | Q1 2023: $203.47 million | Q3 2023: $160.33 million | Q4 2023: $138.74 million | Q1 2024: $113.97 million | Q3 2024: $200.20 million | Q4 2024: $160.83 million | Q4 2024: $294.82 million | Q1 2025: $275.99 million | Q2 2025: $250.77 million | Q3 2025: $215.51 million | Q3 2025: $339.93 million.
- Over the full 12 years of available data (2014 to 2025), KalVista Pharmaceuticals, Inc.'s Total Assets has grown by 3,674.4%.
- Historical annual values: Fiscal year 2025: $250.77 million | Fiscal year 2024: $235.40 million | Fiscal year 2023: $183.20 million | Fiscal year 2022: $203.88 million | Fiscal year 2021: $272.01 million | Fiscal year 2020: $92.53 million | Fiscal year 2019: $118.13 million | Fiscal year 2018: $61.39 million | Fiscal year 2017: $34.35 million | Fiscal year 2016: $24.75 million | Fiscal year 2015: $56.79 million | Fiscal year 2014: $6.64 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: